Overview
Medpace Holdings, Inc. is a global contract research organization (CRO) serving the biotechnology, pharmaceutical and medical-device industries. It provides outsourced clinical development services from Phase I through Phase IV, with therapeutic expertise that includes oncology, metabolic disease, cardiology, infectious diseases and central nervous system disorders. Its stated mission is “to accelerate the global development of safe and effective medical therapeutics.” [1]
Founded in 1992, Medpace is headquartered in Cincinnati, Ohio, and operates across North America, Europe, Asia, South America, Africa and Australia.[2][3] The company reports more than 6,000 associates across 44 countries.[4] For 2025, it reported revenue of approximately $2.53 billion.[5] [1][2][3][4][5][4]
Products & services
Medpace provides clinical-trial services spanning study design and planning, medical monitoring, regulatory-agency engagement, feasibility assessment, study start-up, ethics submissions, and site contracting. Its clinical operations include trial management through its proprietary ClinTrak system, site and patient recruitment support, in-person and virtual monitoring, and risk-based oversight. Medpace also offers regulatory strategy and documentation, medical writing, clinical-data specification and validation, biostatistics, and adverse-event and safety management. Its areas of therapeutic expertise include oncology, metabolic disease, cardiology, antiviral and anti-infective research, and CNS.[6][7][8][9][10][11][12][13][14][15][1]
Technology and specialized services include TrialPACE for electronic patient-reported outcome data collection, eDiary and eConsent, and decentralized-trial options such as wearables, telehealth, home health, and direct-to/from-patient services.[16][17] Laboratory and clinic capabilities include central laboratory testing, specialized biomarker and molecular/genetic testing, biorepository and specimen management, imaging and cardiovascular core labs, standardized ECG services, and a GLP bioanalytical laboratory offering method development and validation, sample analysis, and metabolite screening. Its flow-cytometry capabilities include panels with more than 20 colors; the company states new panels typically require 14–16 weeks of validation.[18][19][20][21][22][23][24]
Medpace reports its operations as one reportable segment and does not provide revenue proportions by product or service line in the cited disclosures.[25] [6][7][8][9][10][11][12][13][14][15][1][18][19][20][21][22][25][16][17][23][24]
Geographic presence
Medpace is headquartered in Cincinnati, Ohio. At December 31, 2025, it had approximately 6,200 employees across 46 countries. Its leased commercial locations span North America, Europe, Asia, South America, Africa, and Australia; it also owns a Leuven, Belgium facility used for laboratory, office, and logistics operations. Its Cincinnati corporate campus comprises five buildings totaling approximately 620,000 square feet.[26][3]
The company’s central laboratories are located in Cincinnati, Leuven, Shanghai, and Singapore.[19] Its central-laboratory services extend across more than 114 countries, while its study start-up operations report trial initiations in over 60 countries.[23][27] [26][3][19][23][27]
Business segments
Medpace Holdings, Inc. reports one operating and reportable segment. Its full-service clinical research business supports Phase I–IV clinical development for biotechnology, pharmaceutical and medical-device customers; the company does not disclose separate reportable segments by service line or therapeutic area.[25][28]
For FY2025, the segment generated $2,530.234 million in revenue—100% of consolidated revenue. Medpace identifies Oncology, Metabolic, Cardiology, Antiviral and Anti-infective, and CNS as areas of therapeutic expertise, but does not report revenue percentages for these areas or for individual services.[29][30][25] [25][28][29][30]
Company history
Medpace was founded on July 1, 1992, by August Troendle, MD, who has led the company since its founding.[31][2] It expanded internationally with an Asia-Pacific presence established in 2004 and EMEA operations in 2005.[32][33]
In July 2012, Medpace opened its Cincinnati Clinical Pharmacology Unit.[34] Cinven announced a majority investment in the company in 2014, and Medpace completed its IPO in 2016, listing on Nasdaq under the ticker MEDP.[35][36] Jesse Geiger became president in 2021; in 2026, he announced his resignation and retirement, with Troendle set to reassume the president role.[37][38] [2][31][32][33][34][35][36][37][38][31][32][33][34][35][36][37]
Sources
- Medpace Holdings, Inc. — Full financial report (2025 Y)
- www.medpace.com[4]
- Medpace Holdings, Inc. — Press release (2025 Y)[5][26]
- www.medpace.com[16]
- www.medpace.com[17]
- www.medpace.com[23]
- www.medpace.com[24]
- www.medpace.com[27]
- Medpace Holdings, Inc. — Full financial report (2026 Q 2)[28]
- www.medpace.com[31]
- www.medpace.com[32]
- www.medpace.com[33]
- www.medpace.com[34]
- www.cinven.com[35]
- www.sec.gov[36]
- medpaceholdingsinc.gcs-web.com[37]
- Medpace Holdings, Inc. — Press release (2026 Q 1)[38]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore Medpace Holdings, Inc. in Finbar ↗